Novo Nordisk touts late-stage trial data for Tresiba insulin injection

Novo Nordisk (NYSE:NVO) touted data today from 2 Phase IIIb trials comparing Tresiba insulin degludec to insulin glargine in adults with Type I and Type II diabetes.
The results were published in the Journal of  the American Medical Association.
The Switch trials are the 1st double-blinded insulin trials to compare the hypoglycemia rates and risks in patients using Tresiba and insulin glargine for Type I diabetes and Type II diabetes.
Get the full story at our sister site, Drug Delivery Business News.
The post Novo Nordisk touts late-stage trial data for Tresiba insulin injection appeared first on MassDevice.

Source: Mass Device - July 3, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Diabetes Drug-Device Combinations Pharmaceuticals Wall Street Beat Novo Nordisk Source Type: news